以糖代谢干预为基础的新药研究与开发  

Drug discovery based on pharmacological interference with glycometabolism

作　　者：孙宏斌[1] 

机构地区：[1]中国药科大学新药研究中心,南京210009

出　　处：《中国药科大学学报》2006年第1期1-8,共8页Journal of China Pharmaceutical University

基　　金：教育部"2005年度新世纪优秀人才支持计划"资助项目;高等学校博士学科点专项科研基金资助项目(No.Y051018);江苏省自然科学基金资助项目(No.BK2005101)~~

摘　　要：糖代谢是能量代谢的核心组成部分,糖代谢异常与许多疾病,如糖尿病、缺血性心脑损伤和肿瘤等重大疾病有密切的关联。因此,通过对各种糖代谢通路进行有针对性的干预,有望开发出新型治疗药物。本文从糖尿病、缺血性心脑损伤、中风、肿瘤等4个方面,综述了近年来以糖代谢干预为基础的新药研究进展。Aim：Glycometabolism makes up the core part of energy metabolism. Abnormalities in glycometabolism is tightly related with some serious diseases, such as type 2 diabetes, ischemic heart and brain diseases, and tumors. Hence it is hopeful to exploit new therapeutic drugs by pharmacological interference glycometabolism pathway. From 4 aspects as diabetes, ischemic heart and brain diseases, strokes and tumors, this paper reviews the research advances of drug development based on interference in glycometabolism.

关 键 词：糖代谢干预 糖原代谢 糖异生 糖酵解 乳酸中毒 

分 类 号：TQ460.1[化学工程—制药化工]